Approach to the Patient With Rheumatologic Disease

The evaluation of musculoskeletal complaints rests on one pivotal question: is this process inflammatory or non-inflammatory? Getting this distinction right at the bedside — through history and examination rather than a spray of tests — frames the entire differential and spares the patient unnecessary investigation.

High-yield: The cardinal signs of inflammation are pain, erythema, swelling, and warmth. Non-inflammatory (mechanical/degenerative) conditions usually lack all of these — except pain. Pain alone does not make a process inflammatory.

1. Inflammatory vs. non-inflammatory arthritis

Autoimmune disease typically presents with inflammation; mechanical and degenerative disorders are characteristically non-inflammatory. The two can coexist in the same patient. The table below is the single most useful bedside comparison.

Feature	Inflammatory	Non-inflammatory
Morning stiffness	>60 min; worsens with immobility ("gelling")	<30 min
Constitutional symptoms	Fever, fatigue, malaise	Generally absent
Examination	Erythema, warmth, soft-tissue swelling, effusions, reduced ROM	Little/no warmth; bony enlargement; effusions possible in OA
Synovial fluid WBC	>2000/µL (neutrophils acutely; monocytes chronically)	200–2000/µL (predominantly monocytes)
Labs	Raised ESR/CRP; anemia of inflammation	Markers normal or minimally raised

Don't miss: Morning stiffness lasting >60 minutes that improves with movement is the hallmark of inflammatory arthritis. Mechanical pain does the opposite — it worsens with use and eases with rest.

2. Approach by joint count

Counting the involved joints narrows the differential faster than almost any test.

Definitions: Monoarthritis = 1 joint · Oligoarthritis = 2–4 joints (typically asymmetric) · Polyarthritis = ≥5 joints (often the small joints of hands/feet).

Monoarthritis

Acute monoarthritis may be non-inflammatory (trauma, hemarthrosis, internal derangement) or inflammatory (crystal-induced, infectious). Chronic inflammatory monoarthritis (>6 weeks) suggests chronic infection (mycobacterial, fungal, Borrelia burgdorferi) or an autoimmune disease; chronic non-inflammatory monoarthritis is usually osteoarthritis.

Treat as septic until proven otherwise: suspicion for infectious arthritis must always be high in acute monoarthritis. Joint aspiration is usually the single most effective diagnostic step.

Oligoarthritis

Acute inflammatory oligoarthritis suggests gonococcal infection or rheumatic fever; chronic inflammatory oligoarthritis points to the seronegative spondyloarthritides (psoriatic arthritis, reactive arthritis, IBD-associated arthritis, ankylosing spondylitis). Chronic non-inflammatory oligoarthritis is usually osteoarthritis.

Polyarthritis

Acute polyarthritis (<6 weeks) is frequently viral — parvovirus B19, HIV, hepatitis viruses, rubella, chikungunya — or may be the opening manifestation of a chronic inflammatory arthritis (RA, SLE, psoriatic arthritis).

3. Soft tissues and the enthesis

Pain with passive range of motion localizes to the joint (articular); pain only with active motion localizes to the surrounding structures (periarticular). Isolated tendon or ligament involvement usually means a non-inflammatory process (overuse, mechanical injury, degeneration — e.g. rotator cuff disease, tennis elbow).

Enthesitis & dactylitis: persistent inflammation at a tendon/ligament insertion (enthesitis), especially at multiple sites, strongly suggests spondyloarthritis. When inflammation extends along the tendon and local ligaments it produces dactylitis ("sausage digits") — a classic feature of psoriatic arthritis.

4. Extra-articular manifestations

Rheumatologic disease is systemic. Constitutional symptoms (low-grade fever, >60-min morning stiffness, disabling fatigue) are common; fever becomes high and spiking in adult-onset Still disease and autoinflammatory syndromes, while disabling fatigue is a hallmark of fibromyalgia. The skin, eyes, and internal organs are frequently involved, and the pattern of involvement helps narrow the diagnosis.

Eyes are an emergency: certain ocular manifestations (e.g. scleritis, ischemic optic neuropathy in giant cell arteritis) can cause permanent vision loss if not recognized and treated rapidly. Painful red eye in a patient with spondyloarthritis is anterior uveitis until proven otherwise.

Selected associations: malar rash → SLE; Gottron papules, heliotrope rash, shawl sign → dermatomyositis; palpable purpura → vasculitis; painful oral/genital ulcers + pathergy → Behçet; erythema chronicum migrans → Lyme; keratoconjunctivitis sicca → Sjögren.

5. Laboratory evaluation

Because these tests have limited specificity, interpret them only in the context of the history and examination, and apply them with great caution — if at all — when pretest probability is low.

Inflammatory markers

ESR rises with fibrinogen and other acute-phase reactants. A practical upper limit of normal is age/2 for men and (age + 10)/2 for women. ESR is also raised in pregnancy, diabetes, obesity, anemia, and end-stage kidney disease, and is falsely low in low-fibrinogen states (liver/heart failure) and polycythemia.

ESR >100 mm/h is a red flag — think giant cell arteritis, multiple myeloma, metastatic cancer, or overwhelming infection/autoimmune disease.

CRP is hepatic, driven mainly by IL-6, and typically rises 2–10× normal in rheumatologic disease; a level >10 mg/dL (>100 mg/L) should prompt consideration of an alternative diagnosis such as infection. CRP responds to change faster than ESR.

Marker of choice differs by disease: CRP tracks activity better in spondyloarthritis, whereas in SLE the ESR is the better activity marker and the CRP may stay normal despite active disease (a raised CRP in SLE often signals superimposed infection).

Complement: C3/C4 are acute-phase reactants that rise in many inflammatory states but fall when consumed by immune-complex disease (SLE, cryoglobulinemic/urticarial vasculitis), infection, and glomerulonephritis. Paradoxically, genetic deficiency of early complement components increases lupus risk.

Autoantibodies

Presence of an autoantibody is not a diagnosis — they lack specificity and occur in other diseases and in healthy people.

RA serology: Rheumatoid factor (IgM anti-Fc of IgG) is present in <70% of RA and is common in endocarditis and hepatitis C. Anti-CCP antibodies are far more specific (~95%) though less sensitive (~67%); together they raise the likelihood of RA, and anti-CCP positivity predicts erosive, rapidly progressive disease. Hepatitis C alone is typically RF-positive but anti-CCP-negative.

ANA cautions: up to one third of healthy people carry a low ANA titer (1:40) and ~5% have ≥1:160. Do not order ANA for nonspecific symptoms with a normal examination — it does not establish a connective-tissue-disease diagnosis. ANA is >95% sensitive for SLE, but the titer does not correlate with SLE activity and must not be used to track it. Reserve ANA sub-serology for ANA-positive patients with a convincing clinical syndrome.

6. Imaging

Plain radiography is the first-line imaging test — readily available, inexpensive, low radiation, and useful for monitoring progression — despite being 2-D and weak for soft tissue and early erosions.

CT is the most sensitive routine modality for bony erosions but adds radiation and cost. MRI is the most sensitive routine modality for soft-tissue abnormalities, inflammation, and fluid collections, and for early spine and sacroiliac inflammation (order it for suspected spondyloarthritis when radiographs are negative, and for suspected osteonecrosis with normal plain films); it avoids radiation but is costly and limited by availability/claustrophobia. Ultrasonography is an inexpensive, real-time, radiation-free way to assess synovitis, tendonitis, bursitis, effusions, and crystal deposition and to guide injections — but it is operator-dependent.

7. Joint aspiration

Aspiration with synovial-fluid analysis is essential to separate inflammatory from non-inflammatory effusions and to distinguish septic arthritis from acute crystal arthropathy. It should be performed in any monoarthritis and whenever infection is considered.

Update since MKSAP 19 (2022): EULAR published a 2022 update of its recommendations for managing RA with synthetic and biologic DMARDs (Ann Rheum Dis, Jan 2023), reaffirming a methotrexate-first, treat-to-target strategy and adding guidance on JAK-inhibitor safety (aligned with the EMA PRAC recommendations). The treat-to-target principle remains central. [2]

Update since MKSAP 19 (2022): The ACR/EULAR remission criteria for RA were revised in 2022 (published Ann Rheum Dis, Jan 2023), updating how remission is defined for treat-to-target decisions — relevant when assessing whether a patient has reached the treatment goal. [3]

References

MKSAP 19 — Rheumatology American College of Physicians (2022). "Approach to the Patient With Rheumatologic Disease," pp. 1–7.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological DMARDs — 2022 update Smolen JS, Landewé RBM, Bergstra SA, et al. Ann Rheum Dis 2023;82:3–18.
ACR/EULAR remission criteria for rheumatoid arthritis — 2022 revision Studenic P, Aletaha D, de Wit M, et al. Ann Rheum Dis 2023;82:74–80.
ACR guideline on exercise, rehabilitation, diet, and integrative interventions for RA (2022) England BR, Smith BJ, Baker NA, et al. Arthritis Care Res 2023;75:1603–15.
ACR guideline on vaccination in rheumatic and musculoskeletal disease (2022) Bass AR, Chakravarty E, Akl EA, et al. Arthritis Care Res 2023;75:449–64.